New Vaccine Breakthrough To Prevent Acne, Is It Really Effective?

Illustration of the vaccine (Pexels/RF. Studio)

Acne is a facial problem faced by many people. Seeing this, a pharmaceutical company called Sanofi made a new breakthrough by making vaccines to prevent acne.

"Helps reshape the landscape of acne treatment," said a Sanofi spokesperson for acne vaccines, quoted from Live Science, on Monday, May 5, 2025.

However, the acne vaccine has not been officially launched. The vaccine is still in the early stages of clinical testing to test its safety and efficacy in adults who have moderate to severe acne.

In the details of the trial that the company shared on its official website, it was stated that this acne vaccine was made using an mRNA structure. In this case, the target protein that is likely to market is a protein made by C.ances, which is acne-triggering bacteria.

The vaccine's phase I/II clinical trial has started in April 2024 and is expected to last until 2027. During that period, the company plans to recruit around 400 adults aged 18 to 45 who have moderate to severe facial acne.

Some participants in the trial will receive one to three doses of the vaccine. Participants will be injected up to three times with the dose during the trial period.

Meanwhile, other test participants will receive a 'dummy' vaccine that does not contain the drug. This will provide a comparison point to help scientists determine how safe and effective the vaccine is.

After the phase I/II clinical trial is complete, another phase I clinical trial will be conducted separately in 2027. In this trial, it is planned to test the effectiveness of the vaccine in treating lighter acne.